CA2719981A1 - Method for the cosmetic treatment of skin ageing - Google Patents
Method for the cosmetic treatment of skin ageing Download PDFInfo
- Publication number
- CA2719981A1 CA2719981A1 CA2719981A CA2719981A CA2719981A1 CA 2719981 A1 CA2719981 A1 CA 2719981A1 CA 2719981 A CA2719981 A CA 2719981A CA 2719981 A CA2719981 A CA 2719981A CA 2719981 A1 CA2719981 A1 CA 2719981A1
- Authority
- CA
- Canada
- Prior art keywords
- gingival
- fibroblast
- fibroblasts
- individual
- mmp
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000000034 method Methods 0.000 title claims abstract description 21
- 230000032683 aging Effects 0.000 title claims abstract description 17
- 239000002537 cosmetic Substances 0.000 title claims abstract description 7
- 210000002950 fibroblast Anatomy 0.000 claims abstract description 85
- 230000002265 prevention Effects 0.000 claims abstract description 8
- 210000003491 skin Anatomy 0.000 claims description 22
- 239000003636 conditioned culture medium Substances 0.000 claims description 21
- 210000004027 cell Anatomy 0.000 claims description 10
- 108010035532 Collagen Proteins 0.000 claims description 8
- 102000008186 Collagen Human genes 0.000 claims description 8
- 229920001436 collagen Polymers 0.000 claims description 8
- 102000016942 Elastin Human genes 0.000 claims description 6
- 108010014258 Elastin Proteins 0.000 claims description 6
- 229920002549 elastin Polymers 0.000 claims description 6
- 230000037303 wrinkles Effects 0.000 claims description 5
- 230000015572 biosynthetic process Effects 0.000 claims description 4
- 210000004207 dermis Anatomy 0.000 claims description 4
- 238000003786 synthesis reaction Methods 0.000 claims description 4
- 238000012258 culturing Methods 0.000 claims description 3
- 239000000284 extract Substances 0.000 claims description 3
- 230000001815 facial effect Effects 0.000 claims description 3
- 238000002347 injection Methods 0.000 claims description 3
- 239000007924 injection Substances 0.000 claims description 3
- 206010040799 Skin atrophy Diseases 0.000 claims description 2
- 230000009759 skin aging Effects 0.000 claims description 2
- 206010040954 Skin wrinkling Diseases 0.000 claims 1
- 230000002500 effect on skin Effects 0.000 description 23
- 102000005353 Tissue Inhibitor of Metalloproteinase-1 Human genes 0.000 description 12
- 108010031374 Tissue Inhibitor of Metalloproteinase-1 Proteins 0.000 description 11
- 239000001963 growth medium Substances 0.000 description 8
- 230000015556 catabolic process Effects 0.000 description 6
- 238000006731 degradation reaction Methods 0.000 description 6
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 5
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 5
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 4
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 4
- 230000007547 defect Effects 0.000 description 4
- 210000002744 extracellular matrix Anatomy 0.000 description 4
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- 238000008157 ELISA kit Methods 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 102000005741 Metalloproteases Human genes 0.000 description 3
- 108010006035 Metalloproteases Proteins 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 102100026802 72 kDa type IV collagenase Human genes 0.000 description 2
- 101710151806 72 kDa type IV collagenase Proteins 0.000 description 2
- 108010076557 Matrix Metalloproteinase 14 Proteins 0.000 description 2
- 102100030216 Matrix metalloproteinase-14 Human genes 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 102100030416 Stromelysin-1 Human genes 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 238000007804 gelatin zymography Methods 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 229920002521 macromolecule Polymers 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000002062 proliferating effect Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 230000035882 stress Effects 0.000 description 2
- VKUYLANQOAKALN-UHFFFAOYSA-N 2-[benzyl-(4-methoxyphenyl)sulfonylamino]-n-hydroxy-4-methylpentanamide Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N(C(CC(C)C)C(=O)NO)CC1=CC=CC=C1 VKUYLANQOAKALN-UHFFFAOYSA-N 0.000 description 1
- 206010068388 Actinic elastosis Diseases 0.000 description 1
- 206010001488 Aggression Diseases 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 102000004954 Biglycan Human genes 0.000 description 1
- 108090001138 Biglycan Proteins 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 102100027995 Collagenase 3 Human genes 0.000 description 1
- 108050005238 Collagenase 3 Proteins 0.000 description 1
- 102000004237 Decorin Human genes 0.000 description 1
- 108090000738 Decorin Proteins 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- 102000016359 Fibronectins Human genes 0.000 description 1
- 108010026132 Gelatinases Proteins 0.000 description 1
- 102000013382 Gelatinases Human genes 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- 101000990902 Homo sapiens Matrix metalloproteinase-9 Proteins 0.000 description 1
- 101000669513 Homo sapiens Metalloproteinase inhibitor 1 Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 102000000380 Matrix Metalloproteinase 1 Human genes 0.000 description 1
- 108010016113 Matrix Metalloproteinase 1 Proteins 0.000 description 1
- 108010016160 Matrix Metalloproteinase 3 Proteins 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 208000012641 Pigmentation disease Diseases 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 102000016611 Proteoglycans Human genes 0.000 description 1
- 108010067787 Proteoglycans Proteins 0.000 description 1
- 101710108790 Stromelysin-1 Proteins 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 102000007000 Tenascin Human genes 0.000 description 1
- 108010008125 Tenascin Proteins 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 230000016571 aggressive behavior Effects 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- OVXZVDMCQPLHIY-QXGOIDDHSA-L calcium;4-[[(2r)-2,4-dihydroxy-3,3-dimethylbutanoyl]amino]butanoate Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCCC([O-])=O OVXZVDMCQPLHIY-QXGOIDDHSA-L 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 210000004177 elastic tissue Anatomy 0.000 description 1
- 108010062572 elaunin Proteins 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- GUAQVFRUPZBRJQ-UHFFFAOYSA-N n-(3-aminopropyl)-2-methylprop-2-enamide Chemical compound CC(=C)C(=O)NCCCN GUAQVFRUPZBRJQ-UHFFFAOYSA-N 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 238000012261 overproduction Methods 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 108010047805 oxytalan Proteins 0.000 description 1
- -1 pH 7.5) Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 210000001626 skin fibroblast Anatomy 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/98—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin
- A61K8/981—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin of mammals or bird
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Dermatology (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Cosmetics (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Enzymes And Modification Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US4089108P | 2008-03-31 | 2008-03-31 | |
| US61/040891 | 2008-03-31 | ||
| PCT/EP2009/053474 WO2009121761A1 (en) | 2008-03-31 | 2009-03-25 | Method for the cosmetic treatment of skin ageing |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2719981A1 true CA2719981A1 (en) | 2009-10-08 |
Family
ID=40809902
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2719981A Abandoned CA2719981A1 (en) | 2008-03-31 | 2009-03-25 | Method for the cosmetic treatment of skin ageing |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20110097421A1 (enExample) |
| EP (1) | EP2257272B1 (enExample) |
| JP (3) | JP2011526585A (enExample) |
| CN (1) | CN102014866B (enExample) |
| AU (1) | AU2009231396B2 (enExample) |
| CA (1) | CA2719981A1 (enExample) |
| DK (1) | DK2257272T3 (enExample) |
| ES (1) | ES2441966T3 (enExample) |
| WO (1) | WO2009121761A1 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8728819B2 (en) | 2006-08-29 | 2014-05-20 | Fibrocell Technologies, Inc. | Methods for culturing minimally-passaged fibroblasts and uses thereof |
| FR2953723B1 (fr) * | 2009-12-11 | 2012-02-24 | Scarcell Therapeutics | Composition pharmaceutique destinee au traitement des pathologies orthopediques |
| KR20140012024A (ko) * | 2010-08-27 | 2014-01-29 | 파이브로셀 테크놀로지스, 인코퍼레이티드 | 국소 진피 제형들 |
| EP2680865B1 (en) | 2011-03-04 | 2017-04-26 | Al-Qahtani, Ahmed H. | Skin cream |
| US20130236427A1 (en) * | 2012-03-07 | 2013-09-12 | Fibrocell Technologies, Inc. | Topical Dermal Formulations and Methods of Personalized Treatment of Skin |
| FR3008316B1 (fr) * | 2013-07-09 | 2020-01-31 | Assistance Publique - Hopitaux De Paris | Utilisation de fibroblastes gingivaux dans le traitement de l'alopecie |
| CA2930556A1 (en) | 2013-11-14 | 2015-05-21 | Dermarche Labs, Llc | Fibroblast mixtures and methods of making and using the same |
| ITUB20152804A1 (it) * | 2015-08-03 | 2017-02-03 | Blast Res S R L | Mezzo di coltura cellulare privo di siero. |
| EP3541399A1 (en) * | 2016-11-18 | 2019-09-25 | Scarcell Therapeutics | Compositions useful for the treatment of immune-related diseases |
| KR102588627B1 (ko) * | 2017-03-08 | 2023-10-16 | 김성진 | Mast4 유전자를 이용한 세포외 기질 생산용 조성물 및 그 제조방법 |
| WO2018183998A1 (en) * | 2017-03-31 | 2018-10-04 | Cellum Biomedical, Inc. | Biocompatible conditioned cell medium compositions and uses thereof |
| IL272145A (en) | 2020-01-20 | 2021-07-29 | Stem Cell Medicine Ltd | Cosmetic preparations with protein concentrate from a conditioned growth medium of stem cells from adipose tissue |
| US12258579B2 (en) | 2023-03-15 | 2025-03-25 | Scarcell Technologies | Mammalian cell population and medicaments for cell therapies in humans and improved cell cultivation methods |
| WO2024189522A1 (en) | 2023-03-15 | 2024-09-19 | Scarcell Therapeutics | Mammalian cell population and medicaments for cell therapies in mammals and improved cell cultivation methods |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6372494B1 (en) * | 1999-05-14 | 2002-04-16 | Advanced Tissue Sciences, Inc. | Methods of making conditioned cell culture medium compositions |
| AU7067200A (en) * | 1999-08-23 | 2001-03-19 | Organogenesis Inc. | Skin care compositions and treatments |
| FR2801771B1 (fr) * | 1999-12-01 | 2003-02-07 | Salomon Sa | Chaussure de sport a rigidite variable |
| US20040101959A1 (en) * | 2002-11-21 | 2004-05-27 | Olga Marko | Treatment of tissue with undifferentiated mesenchymal cells |
| GB0228409D0 (en) * | 2002-12-06 | 2003-01-08 | Thromb X Nv | Pharmacological vitreolysis |
| JP4462865B2 (ja) * | 2003-07-22 | 2010-05-12 | 株式会社ノエビア | 光毒性抑制剤、細胞賦活剤、及びｖｅｇｆ産生促進剤 |
| US7803522B2 (en) * | 2004-02-13 | 2010-09-28 | Human Matrix Sciences, Llc | Elastin producing fibroblast formulations and methods of using the same |
| FR2872431B1 (fr) * | 2004-07-02 | 2007-07-20 | Univ Rene Descartes Paris V Et | Utilisation de fibroplastes gingivaux en therapie cellulaire vasculaire |
| JP4982865B2 (ja) * | 2005-06-29 | 2012-07-25 | 国立大学法人名古屋大学 | 皮膚組織改善材及びその利用 |
| JP5500757B2 (ja) * | 2006-02-17 | 2014-05-21 | ワミレスコスメティックス株式会社 | 海洋深層水濃縮物含有組成物及びその製造方法 |
| CA2660434C (en) * | 2006-08-10 | 2016-09-27 | Universite Rene Descartes-Paris V | Use of gingival fibroblasts for treating a skin wound |
| WO2008081818A1 (ja) * | 2006-12-28 | 2008-07-10 | National University Corporation Nagoya University | 皮膚組織改善材およびその製造方法 |
-
2009
- 2009-03-25 DK DK09728453.3T patent/DK2257272T3/da active
- 2009-03-25 US US12/935,373 patent/US20110097421A1/en not_active Abandoned
- 2009-03-25 AU AU2009231396A patent/AU2009231396B2/en active Active
- 2009-03-25 CN CN200980115587.8A patent/CN102014866B/zh active Active
- 2009-03-25 ES ES09728453.3T patent/ES2441966T3/es active Active
- 2009-03-25 CA CA2719981A patent/CA2719981A1/en not_active Abandoned
- 2009-03-25 JP JP2011502342A patent/JP2011526585A/ja not_active Withdrawn
- 2009-03-25 WO PCT/EP2009/053474 patent/WO2009121761A1/en not_active Ceased
- 2009-03-25 EP EP09728453.3A patent/EP2257272B1/en active Active
-
2014
- 2014-11-10 JP JP2014227713A patent/JP2015057419A/ja active Pending
-
2016
- 2016-10-07 JP JP2016198802A patent/JP2017014277A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2011526585A (ja) | 2011-10-13 |
| CN102014866A (zh) | 2011-04-13 |
| EP2257272B1 (en) | 2013-09-25 |
| JP2015057419A (ja) | 2015-03-26 |
| CN102014866B (zh) | 2014-11-05 |
| DK2257272T3 (da) | 2014-01-20 |
| AU2009231396B2 (en) | 2015-05-07 |
| JP2017014277A (ja) | 2017-01-19 |
| AU2009231396A1 (en) | 2009-10-08 |
| EP2257272A1 (en) | 2010-12-08 |
| US20110097421A1 (en) | 2011-04-28 |
| ES2441966T3 (es) | 2014-02-07 |
| WO2009121761A1 (en) | 2009-10-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2257272B1 (en) | Method for the cosmetic treatment of skin photo-ageing | |
| US8901160B2 (en) | Heparanase activity inhibitor | |
| US9138400B2 (en) | Cosmetic use of skin cell autophagy activators | |
| AU2015381703B2 (en) | Oleanoyl peptide composition and collagen enhancement | |
| Wong et al. | Influence of cytokines on matrix metalloproteinases produced by fibroblasts cultured in monolayer and collagen gels | |
| Lee et al. | The effects of epigallocatechin-3-gallate on extracellular matrix metabolism | |
| US20250064719A1 (en) | Cosmetic composition for anti-aging or wrinkle reduction comprising culture broth of neural stem cells as active ingredient and method of preparing same | |
| US20030152597A1 (en) | Use of at least one sapogenin for prevening the skin or ageing symptoms | |
| Dumas et al. | In vitro biosynthesis of type I and III collagens by human dermal fibroblasts from donors of increasing age | |
| Gaultier et al. | Effects of a vegetable extract from Lupinus albus (LU105) on the production of matrix metalloproteinases (MMP1, MMP2, MMP9) and tissue inhibitor of metalloproteinases (TIMP1, TIMP2) by human gingival fibroblasts in culture | |
| Hwang et al. | Neural stem cells and the secreted proteins TIMPs ameliorate UVB-induced skin photodamage | |
| Xia et al. | Arecoline and oral keratinocytes may affect the collagen metabolism of fibroblasts | |
| KR101068763B1 (ko) | 엘라직산을 함유하는 자외선에 의한 피부노화 억제용 조성물 | |
| JP2004536781A (ja) | 選択的ｍｍｐ阻害剤を用いて皮膚を保護し、回復させるための方法および組成物 | |
| KR102504644B1 (ko) | Atage-905 콜라겐 엘라스틴 혼합물을 포함하는 피부노화 예방 식품 조성물 | |
| Orsini et al. | Matrix metalloproteinase-2 expression induced by two different adhesive systems on human pulp fibroblasts | |
| Chinnathambi et al. | Human skin and gingival keratinocytes show differential regulation of matrix metalloproteinases when combined with fibroblasts in 3‐dimensional cultures | |
| US20110178167A1 (en) | Method for inhibiting activity and/or expression of matrix metalloproteinase, inhibiting phosphorylation of mitogen-activated protein kinase, and/or promoting expression of collagen using terminalia catappa leaf extract | |
| Pavelić et al. | Protective Role of Transforming Growth Factor β (TGF β) in Tumor-Induced Degradation of Basement Membranes | |
| Landeau et al. | Increased secretion of latent elastase activity following contact between human skin fibroblasts and elastin derived peptides. | |
| CN108578265A (zh) | 修护原液及其制备方法和应用 | |
| KR101637640B1 (ko) | 해양 미세조류 파블로바 루테리의 발효물 유래의 펩타이드 및 이를 함유하는 암 예방 및 치료용 약학적 조성물 | |
| Kim et al. | Arazyme prevents skin aging through regulation of matrix metalloproteinase and collagen synthesis | |
| TWI399209B (zh) | 豬肺萃取物作為基質金屬蛋白酶抑制劑之用途 | |
| CN108721136A (zh) | 修护凝胶及其制备方法和应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20140214 |
|
| FZDE | Discontinued |
Effective date: 20181010 |